Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $53.64

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $53.64.

MIRM has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their target price on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th. Baird R W raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Monday, June 17th. Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, June 17th. Finally, Citigroup lifted their price objective on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th.

Mirum Pharmaceuticals Trading Down 2.8 %

Shares of NASDAQ:MIRM opened at $39.07 on Thursday. The firm has a fifty day moving average of $30.98 and a two-hundred day moving average of $28.08. The firm has a market capitalization of $1.84 billion, a P/E ratio of -10.53 and a beta of 1.15. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $40.75. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). The company had revenue of $69.22 million for the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. On average, equities analysts expect that Mirum Pharmaceuticals will post -1.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the completion of the transaction, the insider now owns 27,406 shares of the company’s stock, valued at approximately $931,804. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the transaction, the insider now owns 27,406 shares in the company, valued at approximately $931,804. The disclosure for this sale can be found here. Insiders sold a total of 35,934 shares of company stock valued at $1,180,156 in the last quarter. Insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of Mirum Pharmaceuticals by 18.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 266,681 shares of the company’s stock worth $7,872,000 after purchasing an additional 42,110 shares during the period. California State Teachers Retirement System increased its stake in Mirum Pharmaceuticals by 672.9% in the fourth quarter. California State Teachers Retirement System now owns 211,111 shares of the company’s stock valued at $6,232,000 after acquiring an additional 183,798 shares during the period. CenterBook Partners LP increased its stake in Mirum Pharmaceuticals by 242.4% in the fourth quarter. CenterBook Partners LP now owns 51,837 shares of the company’s stock valued at $1,530,000 after acquiring an additional 36,699 shares during the period. TD Asset Management Inc bought a new stake in Mirum Pharmaceuticals in the fourth quarter valued at about $1,387,000. Finally, Boone Capital Management LLC increased its stake in Mirum Pharmaceuticals by 25.7% in the fourth quarter. Boone Capital Management LLC now owns 490,139 shares of the company’s stock valued at $14,469,000 after acquiring an additional 100,348 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.